Compare Berkshire Hathaway Inc Class B (BRK.B) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Sanofi SA — how do they compare? Berkshire Hathaway Inc Class B trades at $490.36, while Sanofi SA trades at $43.59 (market cap $102.91B). The key difference: Sanofi SA pays a 5.6% dividend while Berkshire Hathaway Inc Class B pays none, and Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| BRK.B | SNY | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $52.34 |
52-Week Low | $459.10 | $41.33 |
Market Cap | — | $102.91B |
Enterprise Value | — | $119.39B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $490.00, down 1.37% on the day. The technical picture shows a bullish moving average signal but neutral oscillators, with immediate support at $489 and resistance at $495. Analyst consensus is bullish with 57% buy ratings and no sell recommendations. The stock's valuation metrics are not provided in the current dataset.
The outlook is cautiously positive based on analyst sentiment and technical positioning near support. Key risks include market volatility and the company's exposure to broad economic cycles. The absence of current fundamental data necessitates direct review of Berkshire Hathaway's latest SEC filings for a complete investment picture.
SNY trades at $44.00, up 1.15% with a bullish technical signal. Recent FDA approvals for Sarclisa and Nexviazyme highlight pipeline strength. Q1 2026 EPS beat expectations at $1.10 versus $1.06. Revenue grew to $46.72B in 2025 with net income margin of 15.95%. Analyst consensus is mixed with 44% buy ratings. The stock shows solid profitability with ROE at 10.29% and manageable debt levels.
Outlook is positive driven by drug approvals and earnings beats, but EU antitrust probes pose regulatory risks. Valuation at P/E 19.51 is reasonable versus peers. Institutional sentiment is cautious with 52% hold ratings. Key catalysts include Q2 2026 results and Sarclisa commercial rollout. Risks include competition and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
